Spain Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes)-Forecast to 2035

Spain Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the Spain Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 88.0 (USD Million) in 2023. The Spain Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 96.0(USD Million) in 2024 to 218.0 (USD Million) by 2035. The Spain Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 7.741% during the forecast period (2025-2035).

Key Spain Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The Spain Dry Age-Related Macular Degeneration (AMD) Market is witnessing significant developments driven by an aging population, as nearly 20% of the Spanish populace is over the age of 65, leading to an increased prevalence of AMD. Government initiatives aimed at enhancing eye health awareness and promoting regular eye examinations are vital market drivers, contributing to early detection and treatment. Furthermore, the rise in healthcare spending in Spain has allowed for improved accessibility to advanced diagnostic tools and treatment options for AMD, helping to address unmet medical needs.

Opportunities to be explored within this market include telemedicine services, which can increase patient access to specialists, particularly in rural areas where healthcare resources may be limited.Spain is in need of modernization due to the fact that a large portion of the population struggles to access specialized care. Also, the collaboration between healthcare professionals and pharmaceutical companies to develop new therapies has the potential to boost treatment effectiveness. From what I have seen, the modern trend appears to be giving increased attention to personalized medicine, focusing on tailoring treatment to a patient's genetic makeup and lifestyle.

With current trends encouraging a shift towards patient-centric care, patients have become more responsible for their treatment regimens, and as a result, many are well-equipped to deal with managing their AMD. Collectively, these trends demonstrate that there is emerging robust attention and strategy toward AMD care in Spain by integrating various levels of patient cognizance, technology, and streamlined treatment options.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Spain Dry Age-Related Macular Degeneration (AMD) Market Drivers

Growing Aging Population in Spain

Spain has one of the highest proportions of elderly individuals in Europe, which is a critical driver for the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. According to data from the National Institute of Statistics, over 19% of Spain's population is aged 65 or older, and this number is projected to increase significantly in the coming years. The aging population is directly linked to the rising incidence of age-related diseases, including AMD, which the World Health Organization reports is expected to affect approximately 196 million individuals globally by 2020 and is expected to escalate to 288 million by 2040.This demographic shift in Spain, driven largely by improvements in healthcare and increased life expectancy, provides a substantial market opportunity for AMD treatments and management solutions, ultimately fueling growth in the Spain Dry Age-Related Macular Degeneration (AMD) Market.

Rising Healthcare Expenditure

The Spanish government's focus on healthcare improvements reflects a significant driver for the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Current reports indicate that Spain's healthcare expenditure has grown steadily, with the government allocating around 10% of its GDP to health services. As the country invests in advanced medical treatments and innovative technologies, the increased funding allows for improved AMD diagnosis and treatment options, fostering the growth of this specific healthcare market.Advocacy from organizations such as the Spanish Society of Ophthalmology emphasizes the importance of adequate resources for eye health, which further supports the demand for AMD therapies and ensures sustainable market growth.

Advancements in Treatment Modalities

Technological innovations and research breakthroughs are adding momentum to the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Recent advancements in treatment modalities, including the development of novel therapeutics and minimally invasive surgical techniques, have transformed AMD care. Clinical trials conducted by notable institutions in Spain have demonstrated positive results with new drug candidates that aim to slow the progression of AMD.For instance, the Spanish Agency of Medicines and Medical Devices reports that innovative drugs hold promise, leading to a rise in prescriptions and boosting the market. This progression in treatment technology can result in improved patient outcomes and increased demand for AMD solutions, further driving market growth.

Growing Awareness and Screening Programs

Increasing awareness regarding AMD and its impact on visual health is a crucial driver in the Spain Dry Age-Related Macular Degeneration (AMD) Market Industry. Ongoing initiatives from organizations like the Spanish Association of Patients with AMD are focusing on educating the public about the importance of early detection and regular eye screenings. A significant 60% of patients remain uninformed about AMD and its repercussions, which is why educational campaigns supported by the Spanish government are essential for promoting regular eye examinations among older adults.This rising awareness leads to higher screening rates and potential early intervention, which can enhance treatment success and stimulate growth in the AMD market sector.

Spain Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The Spain Dry Age-Related Macular Degeneration (AMD) Market, particularly regarding the Stage segmentation, reveals a multifaceted landscape driven by the increasing prevalence of age-related ocular conditions among the aging population. The ongoing demographic shifts in Spain, marked by an increasing number of individuals aged 65 and above, are expected to further catalyze the growth of this market segment. As one of the key contributors to visual impairment in older adults, early age-related macular degeneration represents a crucial starting point for effective intervention. Identifying this stage allows for timely management and proactive measures, which can significantly improve a patient’s quality of life and slow disease progression.

Moreover, the intermediate age-related macular degeneration stage is characterized by noticeable vision changes that often prompt patients to seek medical attention, subsequently creating opportunities for advances in treatment options and patient education programs. With the market focusing on early detection and personalized treatment plans, the demand for diagnostic tools and therapeutic solutions is anticipated to increase, ultimately supporting the overall market growth in Spain. Lastly, the late age-related macular degeneration stage often results in significant vision loss, emphasizing the need for robust healthcare strategies and societal awareness initiatives to assist affected individuals.

The late stage often demands more complex interventions, underscoring the importance of healthcare policies that address patient needs and support long-term care. The combination of these factors illustrates the variety and significance of the Stage segmentation within the Spain Dry Age-Related Macular Degeneration (AMD) Market, reflecting mandatory trends toward improving patient outcomes and meeting the growing demands of an aging population while ensuring access to necessary medical resources. The integral role of government support and healthcare investments in combating AMD also shapes the market dynamics.

Healthcare reforms aimed at increasing affordability and accessibility to eye care services are essential in empowering patients at all stages of the disease, further catalyzing the development of innovative therapies within the Spain Dry Age-Related Macular Degeneration (AMD) Market. Ultimately, the insights derived from this market segmentation will serve as a guiding framework for stakeholders aiming to enhance service delivery, promote preventative measures, and support clinical advancements in AMD management in Spain.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The Spain Dry Age-Related Macular Degeneration (AMD) Market exhibits a significant emphasis on age group segmentation, particularly as the population ages. Individuals above 75 years comprise a critical segment, given that they experience age-related health conditions, including AMD, at higher rates. This age group is crucial as it often leads to a greater demand for healthcare services and interventions, which translates to an increased focus on treatment options available for AMD. Following closely, those above 60 years represent another major demographic, characterized by heightened awareness and a growing desire to maintain their quality of life as they age.

This segment is particularly focused on preventive measures and early intervention strategies. Additionally, the age group above 40 years is increasingly relevant, as proactive health monitoring begins in this bracket. As lifestyle factors and genetic predispositions contribute to the development of AMD, this age group plays an essential role in market growth, driven by rising health consciousness and the pursuit of innovative treatment options. With a steadily aging population, the trends in the Spain Dry Age-Related Macular Degeneration (AMD) Market suggest a robust need for targeted healthcare solutions and advancements in therapy for each age group effectively.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The Spain Dry Age-Related Macular Degeneration (AMD) Market within the Diagnosis and Treatment segment is experiencing notable growth, driven by an increasing aging population and rising awareness about eye health. The focal importance of treatment options in this market stems from the need for effective management strategies, as Dry AMD significantly affects the quality of life. With government initiatives supporting vision health, healthcare providers are expanding access to advanced treatments, fostering innovation in therapies and diagnostic technologies.Diagnosis plays a crucial role in early intervention, enabling timely management and reducing the impact of the disease.

The segment's strength is evident as it addresses a growing patient base and engages in research efforts to develop new diagnostic tools, enhancing accuracy and efficiency. This focus on patient-centric solutions is indicative of the Spain Dry Age-Related Macular Degeneration (AMD) Market's commitment to improving outcomes and meeting the evolving demands of both patients and healthcare professionals. Overall, the segment is poised for growth, propelled by advancements in treatment modalities and a deeper understanding of Dry AMD, supporting a more informed approach to prevention and management within the healthcare system in Spain.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The Route of Administration segment within the Spain Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in determining treatment efficacy and patient compliance. Oral medications have gained attention due to their ease of use, offering a non-invasive alternative that increases patient adherence to treatment regimens. This is particularly important in a country like Spain, where an aging population presents a growing demographic of AMD patients. On the other hand, injectables remain significant in this market, providing targeted therapy through intravitreal injections that directly influence the affected area.The preference for injectables often stems from their ability to achieve rapid therapeutic effects, which is critical for managing disease progression in AMD patients.

The increasing incidence of AMD in Spain fosters a competitive landscape in the administration routes, leading to innovations and advancements in drug formulation and delivery systems. Overall, the combination of oral and injectable routes enhances treatment options and reflects the evolving landscape of the Spain Dry Age-Related Macular Degeneration (AMD) Market.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The Spain Dry Age-Related Macular Degeneration (AMD) Market demonstrates a diverse composition of End Users, encompassing hospitals clinics, diagnostic centers, and academic research institutes. Hospitals and clinics play a vital role by providing foundational patient care and specialized AMD treatment, which drives patient outreach and awareness. Diagnostic centers significantly contribute to early detection, enhancing treatment outcomes for AMD, thereby emphasizing the importance of timely interventions. Academic and research institutes are instrumental in advancing AMD knowledge, fostering innovations that improve diagnostic techniques and therapeutic options, ultimately benefiting the healthcare landscape.

These segments collectively serve as the backbone of the AMD market in Spain, reflecting a well-structured approach to managing a growing patient population affected by AMD, driven by demographic shifts and an increasing emphasis on eye health. This strategic alignment among different End Users not only underscores their importance in the market but also highlights collaborative opportunities for advancing treatment methodologies and patient education. The significance of these segments is further underpinned by ongoing research initiatives and public health campaigns aimed at enhancing awareness and access to care for the aging population in Spain.

Spain Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The Spain Dry Age-Related Macular Degeneration (AMD) Market is characterized by a competitive landscape that is rapidly evolving, driven by advancements in treatment options, awareness programs, and an increasing patient population. Companies operating within this market are focused on developing innovative therapies aimed at addressing the needs of AMD patients while dealing with the challenges of regulatory compliance and market entry barriers. The landscape features a blend of large pharmaceutical enterprises and specialized biotechnology firms that are actively investing in research and development to bolster their product pipelines and enhance their market share. The competitive dynamics are influenced by factors such as pricing strategies, distribution channels, partnerships, and collaborations, all aimed at improving patient outcomes and gaining a foothold in this lucrative sector.

Horizon Therapeutics has established a significant presence in the Spain Dry Age-Related Macular Degeneration (AMD) Market, leveraging its expertise in rare diseases and high unmet medical needs to cater to the AMD patient population effectively. The company boasts a robust portfolio of treatments that enhance its competitive edge while contributing to improved patient management and therapeutic outcomes. Horizon Therapeutics places a strong emphasis on research and clinical trials, thereby showcasing its commitment to innovation and comprehensive care strategies. This focus on cutting-edge research facilitates the development of tailored treatments for AMD, positioning the company as a key player within the Spanish market. Moreover, its strategic partnerships with healthcare professionals and advocacy groups help in raising awareness and improving access to treatments for patients suffering from dry AMD.

Avanir Pharmaceuticals, while focusing primarily on patients with neurological disorders, has also started to make strides within the Spain Dry Age-Related Macular Degeneration (AMD) Market. The company is recognized for its innovative therapeutic solutions that address various challenges faced by AMD patients, particularly in enhancing the quality of vision and managing associated symptoms. Avanir Pharmaceuticals’ key products include treatments that have shown efficacy in improving patient outcomes.

The company continues to explore strategic collaborations and potential mergers to expand its market footprint in Spain, thereby fortifying its position in the AMD landscape. This strategy not only broadens their service offerings but also enables them to tap into new segments of the market, reaffirming their commitment to advancing healthcare solutions for patients in need. Through focused investments and collaboration initiatives, Avanir Pharmaceuticals aims to contribute significantly to the improvement of AMD care in Spain.

Key Companies in the Spain Dry Age-Related Macular Degeneration (AMD) Market Include

• Horizon Therapeutics


• Avanir Pharmaceuticals


• Genentech


• Oxurion


• AGTC


• Bausch Health Companies


• Sivantos


• Roche


• Novartis


• Santen Pharmaceutical


• Alimera Sciences


• Eyenovia


• Regeneron Pharmaceuticals


• Apellis Pharmaceuticals

Spain Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

In the Spain Dry Age-Related Macular Degeneration (AMD) Market, recent developments highlight significant activity among key players such as Horizon Therapeutics, Avanir Pharmaceuticals, Genentech, and Regeneron Pharmaceuticals. Growth in market valuation has been observed, particularly with reports in June 2023 indicating increased investments in research and development from companies like Roche and Novartis aimed at advancing treatment options. Current affairs show a heightened focus on innovative therapies, with Alimera Sciences and Eyenovia enhancing their research collaborations to expedite product development. Notably, in April 2023, Genentech's advancement in clinical trials for new AMD therapies has heightened competition in the Spanish market, further encouraging investment.

Additionally, a merger in May 2023 involving Bausch Health Companies and another key player has drawn attention, reflecting consolidation trends within the industry. Over the past two to three years, significant governmental initiatives have emerged in Spain to combat AMD, including increased funding for eye care research, which has positively influenced stakeholder engagement and market dynamics. The growing prevalence of AMD in the aging population of Spain emphasizes the urgent need for effective therapies and enhances the market's potential for growth and innovation.

Spain Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook


• Early Age-Related Macular Degeneration


• Intermediate Age-Related Macular Degeneration


• Late Age-Related Macular Degeneration


• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook


• Above 75 years


• Above 60 years


• Above 40 years


• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook


• Treatment


• Diagnosis


• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook


• Oral


• Injectables


• Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook


• HospitalsClinics


• Diagnostic Centers


• AcademicResearch Institutes

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	88.0(USD Million)
MARKET SIZE 2024	96.0(USD Million)
MARKET SIZE 2035	218.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.741% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Horizon Therapeutics, Avanir Pharmaceuticals, Genentech, Oxurion, AGTC, Bausch Health Companies, Sivantos, Roche, Novartis, Santen Pharmaceutical, Alimera Sciences, Eyenovia, Regeneron Pharmaceuticals, Apellis Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Increasing elderly population, Growing awareness campaigns, Advancements in treatment options, Rising telemedicine adoption, Expanding healthcare reimbursement policies
KEY MARKET DYNAMICS	aging population, increasing prevalence, technological advancements, rising healthcare expenditure, awareness and education initiatives
COUNTRIES COVERED	Spain